Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects
relevant to the chronic complications of type 2 diabetes. Although GLP-1RAs attenuate T cell …

Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …

The incidence of hepatocellular carcinoma (HCC) is rapidly rising largely because of
increased obesity leading to nonalcoholic steatohepatitis (NASH), a known HCC risk factor …

The human gastrointestinal tract is populated with a diverse microbial community. The vast
genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every …

Type 2 diabetes mellitus (T2DM) is characterized by tissue-specific insulin resistance and
pancreatic β-cell dysfunction, which result from the interplay of local abnormalities within …